



IFW  
Receipt

PATENT  
Attorney Docket No. 056291-5186

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: <b>Ingemar STARKE et al.</b>	)	Confirmation No.: <b>7197</b>
	)	
Application No.: <b>10/511,984</b>	)	Group Art Unit: <b>1624</b>
	)	
Filed: <b>October 21, 2004</b>	)	Examiner: <b>Bruck Kifle</b>
	)	
For: <b>BENZOTHIADIAZEPINE DERIVATIVES, )</b>		
<b>PROCESSES FOR THEIR PREPARATION )</b>		
<b>AND PHARMACEUTICAL )</b>		
<b>COMPOSITIONS CONTAINING THEM (as )</b>		
<b>amended)</b>	)	Date: <b>January 10, 2007</b>

REQUEST FOR CORRECTED OFFICIAL FILING RECEIPT

Commissioner for Patents  
U.S. Patent and Trademark Office  
Customer Window, **Mail Stop Amendment**  
Randolph Building  
401 Dulany Street  
Alexandria, VA 22314


Sir:

It is respectfully requested that the title of the above-referenced application be corrected as noted above. The originally-filed PCT application was entitled "Chemical Compounds" however, the Declaration submitted with the national stage (the current application) clearly indicated the title -- **BENZOTHIADIAZEPINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM --**. A copy of the executed Declaration as filed is attached hereto. A corrected Official Filing Receipt is requested.

Respectfully Submitted,  
**Morgan Lewis & Bockius LLP**

Date: **January 10, 2007**  
Morgan Lewis & Bockius LLP  
Customer No. **09629**  
1111 Pennsylvania Avenue, N.W.  
Washington, D.C. 20004  
Tel. No.: 202-739-3000

By:

  
\_\_\_\_\_  
Donald J. Bird  
Registration No. 25,323  
Tel. No.: (202) 739-5320  
Fax No.: (202) 739-3001



RECEIVED 2 OCT 2004

10/3/04

**COMBINED DECLARATION FOR PATENT APPLICATION AND POWER OF ATTORNEY**

U.S. DEPARTMENT OF COMMERCE

Patent and Trademark Office

ATTORNEY DOCKET NO.:

AstraZeneca Ref.: 100698-1P US

As a below named inventor, I hereby declare that:

**STARKE, Ingemar; DAHLSTROM, Mikael, Ulf, Johan; NORDBERG, Mats, Peter; ALENFALK, Suzanne, WALLBERG, Andreas, Christer and BOSTROM, Stig, Jonas**

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

**BENZOTHIADIAZEPINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM**

The specification of which:

is attached hereto; or

was filed as United States application Serial No. \_\_\_\_\_ on \_\_\_\_\_ and was amended on \_\_\_\_\_ (if applicable); or

was filed as PCT international application Number PCT/GB03/01742 on 23 April 2003 (23.04.2003) and was amended under PCT Article 19 on \_\_\_\_\_ (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the U.S. Patent and Trademark Office information which is material to the patentability of claims presented in this application in accordance with Title 37, Code of Federal Regulations Section 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d) or Section 365(b) of any foreign application(s) for patent or inventor's certificate or Section 365(a) of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign applications(s) for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed.

**PRIOR FOREIGN APPLICATION(S):**

COUNTRY (if PCT, indicate PCT)	APPLICATION NUMBER	DATE OF FILING (day, month, year)	PRIORITY CLAIMED
GB	0209467.0	25 April 2002 (25.04.2002)	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
			<input type="checkbox"/> Yes <input type="checkbox"/> No
			<input type="checkbox"/> Yes <input type="checkbox"/> No

**Combined Declaration for Patent Application and Power of Attorney - (Continued)**  
**(includes Reference to PCT International Applications)**  
**ATTORNEY DOCKET NO.:**  
**AstraZeneca Ref.: 100698-1P US**

I hereby claim the benefits under Title 35, United States Code Section 119(e) of any United States provisional application(s) listed below.

**U.S. PROVISIONAL APPLICATIONS**

U.S. PROVISIONAL APPLICATION NO.	U.S. FILING DATE

I hereby claim the benefit under Title 35, United States Code, Section 120 of any United States application(s) or Section 365(c) of any PCT international application(s) designating the United States of America that is/are listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in that/those prior application(s) in the manner provided by the first paragraph of Title 35, United States Code, Section 112, I acknowledge the duty to disclose to the U.S. Patent and Trademark Office all information known to me to be material to the patentability of claims presented in this application in accordance with Title 37, Code of Federal Regulations, Section 1.56 which became available between the filing date of the prior application(s) and the national or PCT international filing date of this application:

**PRIOR U.S. APPLICATIONS OR PCT INTERNATIONAL APPLICATIONS DESIGNATING THE U.S. FOR BENEFIT:**

U.S. OR PCT INTERNATIONAL APPLICATIONS		STATUS (Check One)		
APPLICATION NO.	FILING DATE	PATENTED	PENDING	ABANDONED
		<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
		<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
		<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
		<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

**POWER OF ATTORNEY:** As a named inventor, I hereby appoint the registered practitioners of Morgan, Lewis & Bockius LLP included in the Customer Number provided below to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith, and direct that all correspondence be addressed to that Customer Number.

Customer Number: **09629**

Direct Telephone Calls To: Donald J. Bird, Reg. No. 25,323, 202-793-5320

**202-739-3000**

Combined Declaration for Patent Application and Power of Attorney - (Continued)  
(includes Reference to PCT International Applications)  
ATTORNEY DOCKET NO.:  
AstraZeneca Ref.: 100698-1P US

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.


FULL NAME OF SOLE OR FIRST INVENTOR	<b>STARKE, Ingemar</b>	
RESIDENCE & CITIZENSHIP	Mölnadäl, Sweden <i>SEX</i>	COUNTRY OF CITIZENSHIP: Sweden
POST OFFICE ADDRESS	AstraZeneca R&D Mölnadäl, SE-431 83 Mölnadäl, Sweden	
FIRST OR SOLE INVENTOR'S SIGNATURE	DATE <i>Ingemar Starke</i> 2004-09-29	
FULL NAME OF SECOND INVENTOR	<b>DAHLSTROM, Mikael, Ulf, Johan</b>	
RESIDENCE & CITIZENSHIP	Mölnadäl, Sweden <i>SEX</i>	COUNTRY OF CITIZENSHIP: Finland
POST OFFICE ADDRESS	AstraZeneca R&D Mölnadäl, SE-431 83 Mölnadäl, Sweden	
SECOND INVENTOR'S SIGNATURE	DATE <i>Mikael Dahlstrom</i> 2004-09-29	

Listing of Inventors Continued on attached page(s): ☒ Yes ☐ No

FULL NAME OF THIRD INVENTOR	<b>NORDBERG, Mats, Peter</b>	
RESIDENCE & CITIZENSHIP	Mölnädal, Sweden <i>SEX</i>	COUNTRY OF CITIZENSHIP: Sweden
POST OFFICE ADDRESS	AstraZeneca R&D Mölnädal, SE-431 83 Mölnädal, Sweden	
THIRD INVENTOR'S SIGNATURE	<i>Mats Nordberg</i>	DATE 2004-09-30
FULL NAME OF FORTH INVENTOR	<b>ALENFALK, Suzanne</b>	
RESIDENCE & CITIZENSHIP	Mölnädal, Sweden <i>SEX</i>	COUNTRY OF CITIZENSHIP: Sweden
POST OFFICE ADDRESS	AstraZeneca R&D Mölnädal, SE-431 83 Mölnädal, Sweden	
FORTH INVENTOR'S SIGNATURE	<i>Suzanne Alenfalk</i>	DATE 2004-09-29
FULL NAME OF FIFTH INVENTOR	<b>WALLBERG, Andreas, Christer</b>	
RESIDENCE & CITIZENSHIP	Mölnädal, Sweden <i>SEX</i>	COUNTRY OF CITIZENSHIP: Sweden
POST OFFICE ADDRESS	AstraZeneca R&D Mölnädal, SE-431 83 Mölnädal, Sweden	
FIFTH INVENTOR'S SIGNATURE	<i>Andreas Wallberg</i>	DATE 2004-09-29
FULL NAME OF SIXTH INVENTOR	<b>BOSTROM, Stig, Jonas</b>	
RESIDENCE & CITIZENSHIP	Mölnädal, Sweden <i>SEX</i>	COUNTRY OF CITIZENSHIP: Sweden
POST OFFICE ADDRESS	AstraZeneca R&D Mölnädal, SE-431 83 Mölnädal, Sweden	
SIXTH INVENTOR'S SIGNATURE	<i>Stig Bostrom</i>	DATE 2004-09-29



UNITED STATES PATENT AND TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE  
 United States Patent and Trademark Office  
 Address: COMMISSIONER FOR PATENTS  
 P.O. Box 1450  
 Alexandria, Virginia 22313-1450  
 www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/511,984	10/21/2004	1614	1340	056291-5186		24	2

CONFIRMATION NO. 7197

09629  
 MORGAN LEWIS & BOCKIUS LLP  
 1111 PENNSYLVANIA AVENUE NW  
 WASHINGTON, DC 20004

## FILING RECEIPT



\*OC000000015400643\*

Date Mailed: 03/11/2005

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

## Applicant(s)

Ingemar Starke, Molndal, SWEDEN;  
 Mikael, Ulf, Johan Dahlstrom, Molndal, SWEDEN;  
 Mats, Peter Nordberg, Molndal, SWEDEN;  
 Suzanne Alenfolk, Molndal, SWEDEN;  
 Andreas, Christer Wallberg, Molndal, SWEDEN;  
 Stig, Jonas Bostrom, Molndal, SWEDEN;

**Power of Attorney:** The patent practitioners associated with Customer Number 09629.

## Domestic Priority data as claimed by applicant

This application is a 371 of PCT/GB03/01742 04/23/2003

## Foreign Applications

UNITED KINGDOM 0209467.0 04/25/2002

**Projected Publication Date:** 06/16/2005

**Non-Publication Request:** No

**Early Publication Request:** No

RECEIVED

MAR 17 2005

MORGAN, LEWIS &amp; BOCKIUS LLP

DOCKETED  
 By LC Date 3/17

Title

~~Chemical compounds~~ BENZOTHIADIAZEPINE DERIVATIVES,  
PROCESSES FOR THEIR PREPARATION AND  
PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Preliminary Class

514

---

**LICENSE FOR FOREIGN FILING UNDER  
Title 35, United States Code, Section 184  
Title 37, Code of Federal Regulations, 5.11 & 5.15**

**GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

**NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).